These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas. Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557 [TBL] [Abstract][Full Text] [Related]
4. Exercise versus airway clearance techniques for people with cystic fibrosis. Heinz KD; Walsh A; Southern KW; Johnstone Z; Regan KH Cochrane Database Syst Rev; 2022 Jun; 6(6):CD013285. PubMed ID: 35731672 [TBL] [Abstract][Full Text] [Related]
5. Psychological interventions for improving adherence to inhaled therapies in people with cystic fibrosis. Dawson S; Girling CJ; Cowap L; Clark-Carter D Cochrane Database Syst Rev; 2023 Mar; 3(3):CD013766. PubMed ID: 36989170 [TBL] [Abstract][Full Text] [Related]
6. Nebulised hypertonic saline for cystic fibrosis. Wark P; McDonald VM; Smith S Cochrane Database Syst Rev; 2023 Jun; 6(6):CD001506. PubMed ID: 37319354 [TBL] [Abstract][Full Text] [Related]
7. Macrolide antibiotics (including azithromycin) for cystic fibrosis. Southern KW; Solis-Moya A; Kurz D; Smith S Cochrane Database Syst Rev; 2024 Feb; 2(2):CD002203. PubMed ID: 38411248 [TBL] [Abstract][Full Text] [Related]
8. Inhaled anti-pseudomonal antibiotics for long-term therapy in cystic fibrosis. Smith S; Rowbotham NJ Cochrane Database Syst Rev; 2022 Nov; 11(11):CD001021. PubMed ID: 36373968 [TBL] [Abstract][Full Text] [Related]
9. [Standard technical specifications for methacholine chloride (Methacholine) bronchial challenge test (2023)]. ; ; Zhonghua Jie He He Hu Xi Za Zhi; 2024 Feb; 47(2):101-119. PubMed ID: 38309959 [TBL] [Abstract][Full Text] [Related]
11. Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis. Skilton M; Krishan A; Patel S; Sinha IP; Southern KW Cochrane Database Syst Rev; 2019 Jan; 1(1):CD009841. PubMed ID: 30616300 [TBL] [Abstract][Full Text] [Related]
12. Probiotics for people with cystic fibrosis. Coffey MJ; Garg M; Homaira N; Jaffe A; Ooi CY Cochrane Database Syst Rev; 2020 Jan; 1(1):CD012949. PubMed ID: 31962375 [TBL] [Abstract][Full Text] [Related]
13. Conventional chest physiotherapy compared to other airway clearance techniques for cystic fibrosis. Main E; Rand S Cochrane Database Syst Rev; 2023 May; 5(5):CD002011. PubMed ID: 37144842 [TBL] [Abstract][Full Text] [Related]
14. Once daily long-acting beta2-agonists and long-acting muscarinic antagonists in a combined inhaler versus placebo for chronic obstructive pulmonary disease. Maqsood U; Ho TN; Palmer K; Eccles FJ; Munavvar M; Wang R; Crossingham I; Evans DJ Cochrane Database Syst Rev; 2019 Mar; 3(3):CD012930. PubMed ID: 30839102 [TBL] [Abstract][Full Text] [Related]
15. Inhaled corticosteroids with combination inhaled long-acting beta2-agonists and long-acting muscarinic antagonists for chronic obstructive pulmonary disease. van Geffen WH; Tan DJ; Walters JA; Walters EH Cochrane Database Syst Rev; 2023 Dec; 12(12):CD011600. PubMed ID: 38054551 [TBL] [Abstract][Full Text] [Related]
16. Digital technology for monitoring adherence to inhaled therapies in people with cystic fibrosis. Smith S; Calthorpe R; Herbert S; Smyth AR Cochrane Database Syst Rev; 2023 Feb; 2(2):CD013733. PubMed ID: 36734528 [TBL] [Abstract][Full Text] [Related]